|
|||||
|
|
WT1 peptide immunotherapy for cancer in children and young adults |
|
| Authors: | Yoshiko Hashii MD PhD Emiko Sato MD Hideaki Ohta MD PhD Yoshihiro Oka MD PhD Haruo Sugiyama MD PhD Keiichi Ozono MD PhD |
| Affiliation: | 1. Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan;2. Department of Respiratory Medicine, Allergy, and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan;3. Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Japan |
| Abstract: | Wilms tumor gene (WT1) can be overexpressed in childhood cancers. We evaluated the efficacy of WT1 vaccination for five children with solid cancer or acute leukemia. WT1 vaccine was administered to HLA‐A*2402‐positive patients with WT1‐overexpressing residual tumor despite prior conventional treatment. One patient showed complete response and one patient showed stable disease according to the Response Evaluation Criteria in Solid Tumors; the remaining three showed progressive disease. Treatment‐related adverse effects were limited to local injection site erythema. These results suggest that WT1 vaccination has therapeutic potential, but any beneficial effect may be insufficient in the presence of gross residual disease. Pediatr Blood Cancer. 2010;55:352–355. © 2010 Wiley–Liss, Inc. |
| Keywords: | cancer children vaccination WT1 peptide young adults |